When choosing between GLP-1 RAs and sodium-glucose cotransporter-2 (SGLT-2) inhibitors - another class that reduces cardiovascular events by primarily mitigating heart failure - the patient's individual risk profile for ischemic versus heart failure complications should guide therapy decisions [39]. This evidence concerns the gene SLC5A2 and heart failure.